JB Pharma Q4 Net Profit Down 30% YoY

JB Chemicals & Pharmaceuticals reported Q4 FY26 revenue of ₹904 crore, down 5% YoY, with net profit declining 30% to ₹101 crore.
Performance was impacted by post-acquisition integration one-offs including distribution optimization, portfolio discontinuation, and practice alignment.
The company expects a progressive recovery starting Q1 FY27, citing the Q4 impact as temporary and noting improved gross margins at 70%.
Full-year FY26 revenue grew 6% to ₹4,148 crore, with EBITDA margin expanding to 29% from 28% in FY25.